In this study, a selective PROTAC degrader of NAT10, NP1192,isdesigned and proved to effectively reduce hypoxia-induced glycolysis,reverse CD8+ T cell dysfunction, and enhance anti-PD-L1therapy, making it a promising cancer immunotherapeutic agent. This evidence concerns the gene CD8A and cancer.